Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration

Inclusion Criteria:

1. Be 55 years of age or older.
2. Have retinal findings of geographic atrophy or disciform scar with foveal involvementas determined by fluorescein angiography or OCT.
3. Have evidence of cataract.
4. Have best-corrected distance visual acuity (BCDVA) no better than 20/80 (0.6 LogMAR)and no worse than 20/800 (1.6 LogMAR) in both eyes.
5. Have adequate peripheral vision in the eye not scheduled for surgery, assessed byobservation of ambulation.
6. Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled forsurgery when using Samsara's 2.8X external telescope simulator (ETS, suppliedseparately).
7. Have an ACD of at least 2.5 mm in the eye scheduled for surgery.
8. Be willing to participate in a post-operative training program for the use of the NGSI IMT 3X implant.
9. Review and sign the Independent Ethics Committee (IEC)-approved Informed Consent Form (ICF) prior to any study-related procedures being performed.
10. Have adequate understanding of the local language to understand verbal and writtensubject information and be willing to comply with the study requirements.

Exclusion Criteria:

1. Evidence of active choroidal neovascularization (CNV) on fluorescein angiography orOCT or were treated for CNV within the past six months.
2. Any ophthalmic pathology that compromises the patient's peripheral vision in thefellow eye.
3. A history of steroid-responsive rise in IOP, uncontrolled glaucoma, or preoperativeIOP>22 mm Hg.
4. Corneal guttata.
5. Known sensitivity to post-operative medications.
6. Significant communication impairment or severe neurological disorders.
7. Have undergone previous intraocular or corneal surgery of any kind in the operativeeye, including any type of surgery for either refractive or therapeutic purposes.
8. An ocular condition that predisposes the patient to eye rubbing.
9. Prior or expected ophthalmic-related surgery within 30 days preceding the NG SI IMT 3Ximplant surgery.
10. Patients for whom the planned operative eye has:

• Myopia > 6.0 D
• Hyperopia > 4.0 D
• Axial length < 21 mm
• Endothelial cell density < 1600 cells per square mm
• Narrow angle, i.e., < Schaffer grade 2.

11. Inflammatory ocular disease.
12. Cornea stromal or endothelial dystrophies, including guttata.
13. Zonular weakness/instability of crystalline lens, or pseudoexfoliation.
14. Diabetic retinopathy.
15. Untreated retinal tears.
16. Retinal vascular disease.
17. Optic nerve disease.
18. A history of retinal detachment.
19. Retinitis pigmentosa.
20. Intraocular tumor.
21. Have received any investigational product within 30 days prior to study enrollment orbe planning to participate in another investigation during the course of this study.
22. Be an employee (or a relative of an employee) of the contract research organization (CRO) responsible for conducting the study, Sponsor, or Sponsor representative.
23. Have a condition or be in a situation that, in the Investigator's opinion, may put theSubject at significant risk, may confound the study results, or may interferesignificantly with the Subject's participation in the study.